AU2020335922B2 - Compositions and methods for treatment of influenza A infection - Google Patents

Compositions and methods for treatment of influenza A infection

Info

Publication number
AU2020335922B2
AU2020335922B2 AU2020335922A AU2020335922A AU2020335922B2 AU 2020335922 B2 AU2020335922 B2 AU 2020335922B2 AU 2020335922 A AU2020335922 A AU 2020335922A AU 2020335922 A AU2020335922 A AU 2020335922A AU 2020335922 B2 AU2020335922 B2 AU 2020335922B2
Authority
AU
Australia
Prior art keywords
antibody
pharmaceutical composition
influenza
days
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020335922A
Other languages
English (en)
Other versions
AU2020335922A1 (en
Inventor
Lynn E. CONNOLLY
Erik MOGALIAN
Phillip S. Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vir Biotechnology Inc
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of AU2020335922A1 publication Critical patent/AU2020335922A1/en
Application granted granted Critical
Publication of AU2020335922B2 publication Critical patent/AU2020335922B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2020335922A 2019-08-29 2020-08-28 Compositions and methods for treatment of influenza A infection Active AU2020335922B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962893747P 2019-08-29 2019-08-29
US62/893,747 2019-08-29
US202062993519P 2020-03-23 2020-03-23
US62/993,519 2020-03-23
US202063040966P 2020-06-18 2020-06-18
US63/040,966 2020-06-18
PCT/US2020/048635 WO2021041989A1 (en) 2019-08-29 2020-08-28 Compositions and methods for treatment of influenza a infection

Publications (2)

Publication Number Publication Date
AU2020335922A1 AU2020335922A1 (en) 2022-03-24
AU2020335922B2 true AU2020335922B2 (en) 2026-06-04

Family

ID=72473986

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020335922A Active AU2020335922B2 (en) 2019-08-29 2020-08-28 Compositions and methods for treatment of influenza A infection

Country Status (11)

Country Link
US (1) US20220306728A1 (cg-RX-API-DMAC10.html)
EP (1) EP4021502A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022545553A (cg-RX-API-DMAC10.html)
KR (1) KR20220061999A (cg-RX-API-DMAC10.html)
CN (1) CN115052630A (cg-RX-API-DMAC10.html)
AU (1) AU2020335922B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022003529A2 (cg-RX-API-DMAC10.html)
CA (1) CA3148990A1 (cg-RX-API-DMAC10.html)
IL (1) IL290752B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022002447A (cg-RX-API-DMAC10.html)
WO (1) WO2021041989A1 (cg-RX-API-DMAC10.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017123685A1 (en) * 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
KR101616758B1 (ko) * 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2016120753A1 (en) * 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
US12304928B2 (en) * 2018-05-18 2025-05-20 Cz Biohub Sf, Llc Epitope restriction for antibody selection
WO2020221450A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017123685A1 (en) * 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CATHARINE I PAULES, LAKDAWALA SEEMA, MCAULIFFE JOSEPHINE M, PASKEL MYEISHA, VOGEL LEATRICE, KALLEWAARD NICOLE L, ZHU QING, SUBBARA: "The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses", JOURNAL OF INFECTIOUS DISEASES, OXFORD UNIVERSITY PRESS, CHICAGO, IL, vol. 216, no. 3, 1 August 2017 (2017-08-01), Chicago, IL, pages 356 - 365, XP055460465, ISSN: 0022-1899, DOI: 10.1093/infdis/jix292 *
PAULINA KOSZALKA, DANIELLE TILMANIS, AERON C. HURT: "Influenza antivirals currently in late-phase clinical trial", INFLUENZA AND OTHER RESPIRATORY VIRUSES, BLACKWELL PUBLISHING LTD, UK, vol. 11, no. 3, 1 May 2017 (2017-05-01), UK, pages 240 - 246, XP055668272, ISSN: 1750-2640, DOI: 10.1111/irv.12446 *

Also Published As

Publication number Publication date
JP2025124708A (ja) 2025-08-26
JP2022545553A (ja) 2022-10-27
BR112022003529A2 (pt) 2022-05-24
KR20220061999A (ko) 2022-05-13
IL290752B2 (en) 2026-02-01
WO2021041989A1 (en) 2021-03-04
IL290752A (en) 2022-04-01
MX2022002447A (es) 2022-08-08
CA3148990A1 (en) 2021-03-04
WO2021041989A9 (en) 2021-05-14
US20220306728A1 (en) 2022-09-29
IL290752B1 (en) 2025-10-01
EP4021502A1 (en) 2022-07-06
AU2020335922A1 (en) 2022-03-24
CN115052630A (zh) 2022-09-13